Fedratinib clinical trials

Studies by the year they started

24 studies that test it; most in 2012 (5)

Who runs them

Industry 20 · Other 4

Bristol-Myers Squibb (13) · Celgene (6) · H. Lee Moffitt Cancer Center and Research Institute (2) · TargeGen (1) · University of Washington (1) · Joseph Jurcic (1)

Often tested with

Tested in the same studies.

Ruxolitinib (2) · Metoprolol (1) · Midazolam (1) · Fluconazole (1) · Digoxin (1) · Rosuvastatin (1) · Metformin (1) · Decitabine (1)

Studies

Open first, then newest update. How each study uses fedratinib is read from its arms, and is right about nine times in ten.

Testing it · 24

• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingPhase 2University of WashingtonNCT04282187Written as Fedratinib
• A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With MyelofibrosisCompletedPhase 1/2Bristol-Myers SquibbNCT00724334Written as SAR302503 (TG101348)
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With MyelofibrosisTerminatedPhase 3Bristol-Myers SquibbNCT01437787Written as SAR302503
• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With RuxolitinibTerminatedPhase 2Bristol-Myers SquibbNCT01523171Written as SAR302503
• Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)CompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05177211Written as Fedratinib Pill
• A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Active, not recruitingPhase 1/2Bristol-Myers SquibbNCT04817007Written as Fedratinib
• Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative NeoplasmsTerminatedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05127174Written as Fedratinib Pill
• A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)Active, not recruitingPhase 1/2Bristol-Myers SquibbNCT04446650Written as Fedratinib
• An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibCompletedPhase 3CelgeneNCT03952039Written as FEDRATINIB
• Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT01762462Written as SAR302503
• Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedPhase 2Bristol-Myers SquibbNCT01692366Written as SAR302503
• Drug Interaction Study of SAR302503 in Patients With Solid TumorCompletedPhase 1Bristol-Myers SquibbNCT01585623Written as SAR302503
• Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT01763190Written as SAR302503
• Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedPhase 2Bristol-Myers SquibbNCT01420770Written as SAR302503
• Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT01836705Written as SAR302503 (TG101348)
• Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedPhase 2Bristol-Myers SquibbNCT01420783Written as SAR302503
• A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With RuxolitinibTerminatedPhase 3CelgeneNCT03755518Written as FEDRATINIB
• Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)TerminatedPhase 1Joseph JurcicNCT05524857Written as Fedratinib Oral Capsule 300 mg
• A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic ImpairmentCompletedPhase 1CelgeneNCT03983161Written as Fedratinib
• A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05051553Written as Fedratinib

See all 24 studies that test fedratinib →

Codes

What other systems call fedratinib · ClinicalTrials.gg INT005259

• MeSH (NLM) C528327fedratinibConfirmed ClinicalTrials.gov, NLM
• UNII (FDA) 6L1XP550I6FEDRATINIBConfirmed FDA, NLM, Wikidata
• RxNorm 2197490One source FDA
• Wikidata Q7670147fedratinibConfirmed FDA, NLM, Wikidata
• NCI Thesaurus C88293FedratinibOne source FDA
• DrugBank DB12500One source Wikidata

Also registered as fedratinib hydrochloride (UNII UH9J2HBQWJ · RxNorm 2197594).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.